Press Releases

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Forma disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title	Additional Formats
Oct 26, 2020	Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML)	PDF Version
Sep 15, 2020	Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions	PDF Version
Sep 09, 2020	Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors	PDF Version
Aug 13, 2020	Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update	PDF Version
Jul 30, 2020	Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors	PDF Version
Jun 23, 2020	Forma Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares	PDF Version
Jun 18, 2020	Forma Therapeutics Announces Pricing of Initial Public Offering	PDF Version
Jun 12, 2020	Forma Therapeutics Presents Safety, Pharmacokinetic And Pharmacodynamic Data From Phase 1 Clinical Trial For Investigational Agent FT-4202 In Patients With Sickle Cell Disease	PDF Version
Jun 09, 2020	Forma Therapeutics Announces Phase I Clinical Data For Investigational Agent FT-4202 In Sickle Cell Disease To Be Presented At The Virtual Edition Of The 25th European Hematology Association Annual Congress	PDF Version
May 28, 2020	Forma Therapeutics Announces Clinical Data To Be Presented At ASCO20 Virtual Scientific Program	PDF Version

© 2020 ALL RIGHTS RESERVED

ADDRESS

500 Arsenal Street, Suite 100
Watertown, MA 02472
617.679.1970

SOCIAL MEDIA